A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Phillip Garfin, MD, PhD
Jazz Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
- Princess Margaret Cancer Center
Toronto, Ontario, Canada
- Cecim Biocinetic
Santiago, Chile
- Centro Internacional de Estudios Clínicos
Santiago, Chile
- Centro de Investigacion Clinica Saga
Santiago, Chile
- Icegclinic Research & Care
Santiago, Chile
- Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
- Pusan National University
Busan, South Korea
- Asan Medical Center
Seoul, South Korea
- Korea University Anam Hospital
Seoul, South Korea
- Seoul National University Hospital
Seoul, South Korea
- Severance Hospital
Seoul, South Korea
- Usc/norris Comprehensive Cancer Center
Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
- H. Lee Moffitt Cancer Center
Tampa, Florida, United States
- University of Chicago
Chicago, Illinois, United States
- the Cancer and Hematology Centers
Grand Rapids, Michigan, United States
- Nebraska Methodist Hospital
Omaha, Nebraska, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Virginia Mason Medical Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Aug 2019
- Primary completion
- 30 Aug 2025
- Completion
- 30 Aug 2025
- Last update posted
- 12 Sept 2025
- Registered enrollment
- 74
- Registry id
- NCT03929666
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.